a review of worldwide experience with sparfloxacin in the treatment of community-acquired pneumonia and acute bacterial exacerbations of chronic bronchitis：在社区获得性肺炎、慢性支气管炎急性发作期治疗细菌司帕沙星全球经验回顾.pdfVIP

下载本文档

6
0
约10.11万字
约 13页
2016-03-12 发布于广东
举报
版权申诉

a review of worldwide experience with sparfloxacin in the treatment of community-acquired pneumonia and acute bacterial exacerbations of chronic bronchitis：在社区获得性肺炎、慢性支气管炎急性发作期治疗细菌司帕沙星全球经验回顾.pdf

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

a review of worldwide experience with sparfloxacin in the treatment of community-acquired pneumonia and acute bacterial exacerbations of chronic bronchitis：在社区获得性肺炎、慢性支气管炎急性发作期治疗细菌司帕沙星全球经验回顾

International Journal of Antimicrobial Agents 12 (1999) 5–17 Review article A review of worldwide experience with sparﬂoxacin in the treatment of community-acquired pneumonia and acute bacterial exacerbations of chronic bronchitis Roger G. Finch * Department of Microbiology and Infectious Diseases, The City Hospital and Uniersity of Nottingham, Nottingham NG5 1PB, UK Received 26 August 1998; accepted 10 September 1998 Abstract The worldwide occurrence of community-acquired pneumonia (CAP) shows an undiminished prevalence of this serious illness and hospitalisation is common in those patients with severe illness. The diversity of bacterial pathogens that can act as aetiologic agents presents a challenge to initial empiric antimicrobial management. In recent years, treatment has been further complicated by an increased incidence of antibiotic resistance in pathogens such as Streptococcus pneumoniae, Haemophilus inﬂuenzae and Moraxella catarrhalis. The newly available ﬂuoroquinolones including sparﬂoxacin offer an alternative approach to empiric management. Sparﬂoxacin is active against many typical and atypical pathogens, as well as strains resistant to conventional agents. In comparative studies, the in vitro potency of sparﬂoxacin and its pharmacokinetic proﬁle have been conﬁrmed. The clinical trial efﬁcacy and safety data suggest it might be a useful empiric therapy for both CAP and acute bacterial exacerbation of chronic bronchitis. © 1999 Elsevier Science B.V. and International Society of Chemotherapy. All rights reserved. Keywords: Sparﬂoxacin; Co